Covered Call Position Established in Insulet Corporation

Today a short-term Covered Call position in Insulet Corporation (PODD) was established when one hundred shares were purchased at $153.06 and one May 15th, 2026 Call option was sold at $10.30 per share at the $145.00 strike price.  The buy/write net debit limit order at $142.76 was executed, so the time value was $2.24 per share [$10.30 Call option premium - ($153.06 stock purchase price - $145.00 strike price)].  Insulet's first quarter earnings were reported after market close yesterday, so there is no earnings report prior to the May 15th options expiration date.  I consider today's very negative stock price decline of over 8% after a beat-and-raise quarter (that also included an increase to their 2026 guidance) to be an unjustified overreaction. But given my current cautious market outlook, an in-the-money Covered Calls position was established with a 73.4% probability of assignment on the options expiration date when this buy/write limit order was executed. 

Insulet Corporation makes, sells, and develops its proprietary Omnipod System, an automated insulin pump for insulin-dependent diabetics in the U.S. and Internationally.  Their business operates on a razor-and-blade model centered on its Omnipod system, pairing its low-cost controller (the razor hardware) with its disposable (replaced every 3 days) insulin pods (the consumable blades) that generate recurring, high-margin revenue and strong cash flow visibility. Financially, the company has delivered a decade of consistent high growth, with revenue expanding from under $1B in 2020 to ~$2.7B in 2025 (roughly a 25–30% annual growth rate in recent years), including its 10th consecutive year of 20%+ growth and accelerating ~30% growth in 2025. Profitability has scaled alongside revenue, with gross margins around ~70%+ and operating leverage improving as volumes increase, though near-term earnings can fluctuate due to reinvestment in sales and R&D. Looking forward, management continues to guide to ~20%+ revenue growth with even faster EPS expansion, driven by international expansion, penetration of the large Type 2 diabetes market, and deeper integration with leading automated insulin delivery ecosystems such as Dexcom's G7 and Abbott's FreeStyle Libre. Overall, Insulet offers investors a rare combination of durable recurring revenue, strong historical execution, and a long runway for growth in an underpenetrated global market.

Insulet is highly rated by analysts.  The average target price of the 25 analysts currently covering the company is +120.5% above today's stock purchase price.  In addtion, Morningstar has a 5-star strong buy rating and CFRA a 4-star buy rating.

As detailed below, a potential return-on-investment result is +1.6% absolute return-on-investment (equivalent to +63.4% annualized return-on-investment over the next 9 days) if the stock is assigned on the May 15th, 2026 options expiration date.

Insulet Corporation (PODD) -- New Covered Call Position
The simultaneous buy/write transaction today was as follows:
5/6/2026 Bought 100 Insulet Corp. shares @ $153.06
5/6/2026 Sold 1 PODD 5/15/2026 $145.00 Call option @ $10.30 per share
Note: the Implied Volatility of the Call was 54.0 when this transaction was executed.  As I prefer, this value exceeds that of the S&P 500 Volatility Index (VIX) which is currently at 17.2.

A possible overall performance result (including commission) for this Insulet Covered Call position if assigned on the options expiration date is as follows:
Covered Call Cost Basis: $14,276.67
= ($153.06 - $10.30) * 100 shares + $.67 commission

Net Profit Components:
(a) Option Income: +$1,029.33
= ($10.30 * 100 shares) - $.67 commission
(b) Dividend Income $0.00
(c) Capital Appreciation (If Insulet shares assigned at the $145.00 strike price on the options expiration date): -$806.00
+($145.00 strike price - $153.06 stock purchase price) * 100 shares

Total Net Profit (If Insulet shares assigned at the $145.00 strike price at the 5/15/2026 expiration date): +$223.33

= (+$1,029.33 option income + $0.00 - $806.00 capital appreciation)

Absolute Return-on-Investment (If PODD shares assigned at the $145.00 strike price on the May 15th, 2026 options expiration date): +1.6%

= +$223.33/$14,276.67

Annualized Return-on-Investment (If Insulet stock assigned at the $145.00 strike at the 5/15/2026 options expiration date): +63.4%

= (+$223.33/$14,276.67) * (365/9 days)